Remaining unmet needs in diverse populations with mHSPC

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

EP: 4.The current treatment landscape of mHSPC

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

EP: 11.Improving diversity in future clinical trials for mHSPC

Now Viewing

EP: 12.Remaining unmet needs in diverse populations with mHSPC

Future Research Directions

Key Themes:

• There is a need for continued efforts to improve minority enrollment in clinical trials.
• The importance of real-world evidence to complement trial data is growing.
• A combined approach should use trial and real-world data for comprehensive assessment.
• Future research should prioritize diversity and representation.

Key Points for Physicians:

• Stay informed about evolving evidence from clinical trials and real-world data.
• Support efforts to improve diversity in research.
• Consider contributing to real-world evidence generation.
• Recognize limitations in current evidence while awaiting more comprehensive data.

Notable Insights: Real-world evidence provides an important complement to clinical trial data, particularly for understanding outcomes in traditionally underrepresented populations.

Clinical Significance: Ongoing commitment to inclusive research and evidence generation will improve the quality and equity of prostate cancer care, particularly for populations historically underrepresented in clinical trials.